ABOUT PHARMA INTEGRATES

12-13 November 2018
Grange Tower Bridge Hotel, London

Pharma Integrates is a unique event bringing together key industry leaders across the Pharmaceutical pipeline to share insights and create debate on crucial topics that influence the future of patient outcomes.

Building on a successful 2017, with a presence of more than 90 prestigious speakers and 350 senior industry executives, the event is moving to a larger venue in Grange Tower Bridge Hotel, London, UK.

The 2018 event will include key speaker slots, panel discussions and networking sessions to encourage debate and establish connections between representatives from the entire pharma community, including biotechs, SMEs, small to large pharma companies, CROs, CDMOs, consultants, patient groups and academics.

Topics already tabled for discussion range from changing pharma’s focus from treatment to prevention, the impact of medtech wearables, developments in cell and gene therapy and surgically removing the industry’s “anticollaboration gene.”

Register Today

SPEAKERS

Pharma Integrates brings together the top leaders in their field, so they can share insights into the current and future states of the industry.

Sir Andrew Dillon
Chief Executive

National Institute for Health & Care Excellence (NICE)

Erik Nordkamp
UK Managing Director

Pfizer

Nathalie Moll
Director General

EFPIA – European Federation of Pharmaceutical Industries & Associations

Brian Henry
Vice President, Drug Product Design

Pfizer Worldwide Research and Development

Following registration and opening remarks on Monday 12th November, there will be an afternoon programme of interviews and plenary panel discussions to which all attendees are invited. The day finishes with an early evening networking drinks reception which is open to all.

On Tuesday 13th November there will be three tracks of panel discussions and boardroom style workshops running in parallel. Tracks and timings for these will be announced shortly

DAY 1

MONDAY 12TH NOVEMBER 2018

12:00 – 13:45 Registration And Networking Refreshments

13:45 – 14:05 Welcome and Opening Remarks Presented by Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)

14:05 – 14:35 Interview with Erik Nordkamp, UK Managing Director, Pfizer

As Brexit, political uncertainty and pricing continue to impact funding and inward investment, does the spectre of regulatory equivalence offer an opportunity to implement change and encourage innovation … or are they incompatible? The old ways are not the new ways, it seems, and panellists will examine Big Pharma’s biggest challenges, such as balancing short-term pressures with long-term disruption, affordability and access, and dealing with value-based healthcare, more empowered patients and a greater focus on prevention in an ambiguous world.

15:35 – 16:05 Networking Refreshment Break

Automated manufacturing and the future of drug processing
Is AI a myth or reality … and can it help pharma R&D to further unlock human biology? Will it improve drug target discovery and what are the opportunities for deep/machine learning to enhance clinical trials, treatment pathways and medicines concordance? How far away are we from 100% automation and are virtual or site-less trials in our immediate future? The panel will tackle these and other thorny issues, such as whether digital therapeutics can complement or substitute medicines, and both around the beyond the pill ventures.

17:05 – 17:35 Interview with Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence (NICE)

17:35 – 19:15 Networking Drinks Reception

DAY 2

TUESDAY 13TH NOVEMBER 2018

Dinosaur or leader: what is pharma in the 21st century?
At nearly 200 years old, it’s easy to think that the pharmaceutical industry might have lost its touch. With Apple, Google, Amazon and DHL lurking in the wings, what do prescribers want? Tackling this question head on, the panel will discuss pharma models of the past and future, assess how healthcare costs can be cut and find out, especially from a regulatory point of view, where the industry currently stands.

Amidst further CDMO consolidation, do mega-CROs or niche equivalents provide a better service?
It has been forecasted by the ISR that R&D funding will increase by $40 billion from 2015 to 2020. But, who will receive it? Attend the panel discussion to find out whether large or small CROs will be driving the innovation of the future and how CDMOs will benefit from the development of new technologies.

Getting the balance right for patients in an era of digital support
With stricter data protection legislation now in effect and the public’s privacy concerns greater than ever, the healthcare sector must ask itself whether there should there be a limit on data collection, how digital technology can play a greater role and whether can we ensure that patient identities are protected.

What’s happening at the edge of innovation?
As work and everyday life move further into the online space, the world of healthcare must follow. Discussing topics such as digital design and operation, the panel will also address the mHealth applications of digital diagnostics and devices and the increasing role that the latest technology innovations are playing in the pharma pipeline.

Building strong and mutually beneficial outsourcing partnerships
An optimised supply chain is one in which the association between the sponsor and the CDMO is both open and mutually respectful. As more and more companies expand into new countries and emerging economies, understanding and agreeing certain issues is key. Among the hurdles to overcome are technology transfer, credible capacity, pricing, IP ownership and exclusivity, all of which will be addressed and tackled by the panel.

Life sciences organisations are eager to take the next steps toward better patient outcomes and service delivery. However, antiquated and inefficient processes, along with regulatory concerns and an inherent caution about applying new technologies, have combined to cause life sciences to trail other industries in exploring the potential of blockchain. This workshop will examine how providing faster access to trusted information, better collaboration and increased transparency, blockchain could go a long way to help transform life sciences in such areas as personalised patient engagement, reduced counterfeit medicines and more effective research and development (R&D).

We’re on the home straight, but are we ready and, if so, for how long?
Regulations are finally being met, but is that the end of the serialisation story? The panel will explore the potential endpoints of track-and-trace technology and what serialisation can offer the industry beyond data collection.

Combining public and private resources to bring new medicines to market faster
No single company is equipped to overcome all the hurdles involved in the increasingly complex process of developing medicines on their own. As such, sharing resources, expertise and data could expedite times to market and provide more resource efficient solutions. Precompetitive partnerships involving regulators, academics, HTAs, patient organisations and the greater bio/pharma industry would offer deeper insight into the design of clinical trials, a vast amount of pooled disease-relevant data and new approaches to implementing novel technologies. Overall, they can play a significant part in accelerating drug development.

Strategic partnerships let pharmaceutical companies streamline how they work with contractors and are changing how CDMOs view outcomes.
Pharma is not an island and requires collaborations and partnerships with multiple organisations and companies to function. In this session, panellists will discuss the pros and cons of working with big versus small companies, explore strategic relationships and examine the benefits of integrated, end-to-end collaborations.

The Biotech Outlook 2018 augured a continued focus on immuno-oncology applications, driven by the growing personalized medicine trend and new trials, a surge of delayed merger and acquisition activity based on the shifting sands of US taxation, and a boom year for the industry. Were the soothsayers right? If so, how will what’s come to pass affect the drug pipelines of the future and how can CDMOs adapt to meet the challenging developments aligned with emerging technologies and new therapeutic modalities?

Shouldn’t the pharmaceutical industry be doing more?
Ultimately, every strand of the pharmaceutical industry has the same endpoint: the patient. But how much do companies really factor in patient needs and viewpoints? Hear the panel weigh in on the value of patient feedback, how pharma can reduce healthcare costs — not just by decreasing COGs but by implementing new supply chains — and what improving the patient experience could mean for the sector.

Within a universal platform of appropriate standards, can industry deliver low cost solutions that work?
Thanks to electronic devices, the world is becoming more and more connected. And with this connectivity comes an opportunity to transform the way in which chronic diseases are managed. Attend the panel to learn how universal platforms are changing the way the industry develops solutions.

What’s pharma’s CM endgame and can the technology deliver on its promises?
The ultimate aim of CM is to get better medicines to market, and patient, in a more efficient and cost-effective way. Integration of continuous manufacturing processes coupled with inline model predictive control can reduce production time and costs, prevent deviations from specifications and facilitate Real Time Release Testing. The onus now is on manufacturers, academics, regulators and suppliers of complementary technologies to work together to facilitate the uptake of continuous manufacturing technologies in the drug production sector. This will require a transformative approach to manufacture design and process incorporating a range of enabling technologies from monitor and control to machine learning and artificial intelligence and a range of others linking to form digital twins. In an era of advanced and personalised medicines, is CM the right tool for the job?

Meeting current and future staff skills and knowledge requirements in the bio/pharmaceutical industry
Looking beyond Brexit, we need to ensure that the UK remains competitive by providing the training required for the future technology needs of the drug manufacturing sector. In this deep dive discussion, facilitated by the Medicines Manufacturing Industry Partnership and the Science Industry Partnership, we will assess your needs and add to the evidence to ensure we can attract, grow, train and certify the talent needed, from apprentices and graduates to data scientists and engineers, to continue to advance the pharmaceutical manufacturing industry and public health.

2017 AGENDA

Recap 2017 Agenda
Register today

EXECUTIVE ADVISORY BOARD

Pharma Integrates is supported by a 25 strong committee of recognised industry experts and leading practitioners

Trevor Jones
Member of the Board & Chairman

eTherapeutics & Simbec Orion Research

Jo Pisani
Partner, UK Pharma and Life Sciences Consulting Lead

Strategy&, part of the PwC network

Mark Cassidy
Head of Strategy and Commercial Operations

Ajinomoto OmniChem

Cornell Stamoran
Vice President, Strategy and Corporate Development

Catalent Pharma Solutions

SPONSORS
Discover more sponsors

REGISTER NOW

Book your ticket to Pharma Integrates 2018 today

Package includes:

  • Access to the full programme of conference interviews and panel debates (both days)
  • Champagne and canapé reception
  • Networking luncheon and refreshment breaks
  • Access to event networking tool
  • Access to all filmed content post event

Book now to secure our early bird delegate rate of £995 + VAT.

Simply click the button to complete online or call us on +44 (0) 20 8667 9551.

Discounts are also available for multiple places for a limited period. Please do call us to discuss your requirements

Register today

REGISTER NOW

Book your ticket to Pharma Integrates 2018 today

Package includes:

  • Access to the full programme of conference interviews and panel debates (both days)
  • Champagne and canapé reception
  • Networking luncheon and refreshment breaks
  • Access to event networking tool
  • Access to all filmed content post event

Book now to secure our early bird delegate rate of £995 + VAT.

Simply click the button to complete online or call us on +44 (0) 20 8667 9551.

Discounts are also available for multiple places for a limited period. Please do call us to discuss your requirements

Register today